Now, the biotech company Celyad is looking for a non-gene-edited approach to create allogeneic CAR-T cells using RNAi. Last October, Celyad announced a collaboration with shRNA experts Dharmacon, a Horizon Discovery company, to use their optimized shRNA technology to create CAR-T therapies.
CAR-T Therapy Development on the Rise
By Michael Tattory|
2019-06-12T08:22:52-04:00
June 11th, 2019|News|Comments Off on CAR-T Therapy Development on the Rise